# NUWIQ®
Antihemophilic Factor (Recombinant)

# DAVE ALDERETE
*Made the Switch to NUWIQ*

**Disclaimer:** The views and opinions expressed in this testimonial are those of the patient and do not necessarily reflect the opinions or recommendations of Octapharma USA. Results vary from patient to patient and treatment should be discussed with your HCP.

> "Many of us in the bleeding disorders community will tell you: less is more. And today, I feel that I'm able to do more while using less."

**Dave was born prematurely and spent the first year of his life in the hospital.** He was diagnosed with hemophilia A at 15 months of age.

**Growing up in the southwest,** Dave describes the biggest challenge of living with hemophilia A was just trying to be a kid and enjoy fun things: basketball, baseball, climbing, and bicycling. "My mother was a single parent for a while, and she didn't like that I played so many sports and participated in other physical activities because it was hard to get me proper treatment." Despite these challenges, Dave excelled in scholastics and graduated from National American University, earning a Bachelor of Science degree in Business Administration.

- Before switching to NUWIQ, Dave was treated with Recombinate®, which he received for 10 years. However, he experienced side effects: rash and irritation as the product was infused. After many years of using the first-generation FVIII concentrate, "It was time for a change," Dave says. "I wanted to see what else was available—and I did not want a FVIII that was made from hamster cells."
- Six months ago, Dave switched to NUWIQ. He worked with his doctor to create a personalized prophylaxis regimen, which only required 2 visits to his HTC for PK testing. "When I finally switched, I had many questions. How will this new product affect me? Will it be better for me? Will there be any side effects?"

## Dave Today | Achieving More After Switching to NUWIQ

"I was on my previous treatment 3 times per week. With NUWIQ, I was able to reduce it to twice per week. I feel like I'm able to do more." Dave also talks about the convenience of NUWIQ when he travels, pointing out that NUWIQ is the only recombinant FVIII that offers 2.5 mL diluent volume across all vial sizes. Finally, Dave says that with NUWIQ, he is getting the bleeding control he has been looking for.

"I would tell anyone who is thinking about switching their FVIII medication to consider NUWIQ. I'm very satisfied with how it works for me. It gets to the bleed fast, and I no longer have to deal with the rash and irritation when infusing. And everything you need is right there in the box: a pre-filled syringe with 2.5 mL diluent, a vial adapter, a butterfly needle, and even alcohol swabs!"

**Indications and Usage**
NUWIQ® is a recombinant antihemophilic factor [blood coagulation factor VIII (Factor VIII)] indicated in adults and children with Hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and for routine prophylaxis to reduce the frequency of bleeding episodes. NUWIQ is not indicated for the treatment of von Willebrand Disease.

**Please see enclosed full Prescribing Information.**
**Please see other side for Important Safety Information.**

# NUWIQ®
Antihemophilic Factor (Recombinant)

# Powerful Bleeding Prevention and Control

### On-Demand Control[2,3]




**91%** resolved with 1 infusion[2]

### Standard Prophylaxis[1]




**0.9** median ABR for all bleeds[1]

### Personalized Prophylaxis[4†]




**83%** of patients had no spontaneous bleeds[4]

*In clinical trials of standard prophylaxis with NUWIQ in adult (N=32) and pediatric (N=59) patients treated for ≥6 months; NUWIQ prophylaxis regimen (every other day or 3 times per week for ≥6 months).
†Prospective, open-label, multicenter phase 3b study evaluating personalized, PK-guided prophylaxis with NUWIQ in 66 adult PTPs with severe hemophilia A.

## Are You Interested In the Possibility of Fewer Weekly Infusions?

**Personalized prophylaxis tailors FVIII dose and dosing frequency to each patient's individual pharmacokinetics**

### The *NuPreviq* Study[4]

Prospective, open-label, multicenter phase 3b study evaluating personalized, PK-guided prophylaxis with NUWIQ in 66 adult PTPs with severe Hemophilia A


**Median Dosing Interval**

**Patients with Dosing Interval of 2X Weekly or Less**


### Contraindications

NUWIQ® is contraindicated in patients who have manifested life-threatening hypersensitivity reactions, including anaphylaxis, to the product or its components. The most frequently occurring adverse reactions (>0.5%) in clinical trials were paresthesia, headache, injection site inflammation, injection site pain, non-neutralizing anti-Factor VIII antibody formation, back pain, vertigo, and dry mouth.

### Warnings and Precautions

Hypersensitivity reactions, including anaphylaxis, are possible with NUWIQ. Early signs of hypersensitivity reactions that can progress to anaphylaxis may include angioedema, chest tightness, dyspnea, wheezing, urticaria, or pruritus. Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur.

The formation of neutralizing antibodies (inhibitors) to Factor VIII can occur following the administration of NUWIQ. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests. If the plasma Factor VIII level fails to increase as expected, or if bleeding is not controlled after NUWIQ administration, suspect the presence of an inhibitor (neutralizing antibody).

**Please see enclosed full Prescribing Information.**

**References: 1.** NUWIQ® full Prescribing Information. Hoboken, NJ: Octapharma USA, Inc.; rev 2017. **2.** Valentino LA, et al. Haemophilia. 2014;20(Suppl1):1-9. **3.** Kessler C, et al. Haemophilia. 2015;21(Suppl1):1-12. **4.** Lissitchkov T, et al. Haemophilia. 2017;23:697-704.


Date of preparation: 10/2019. NUW-0234-COT

octapharma®
For the safe and optimal use of human proteins